- Home
- PKE vs ADCT Comparison
PKE vs ADCT Comparison
Compare PKE & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- ADCT
- Stock Information
- Founded
- PKE 1954
- ADCT 2011
- Country
- PKE United States
- ADCT Switzerland
- Employees
- PKE N/A
- ADCT N/A
- Industry
- PKE Military/Government/Technical
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- PKE Industrials
- ADCT Health Care
- Exchange
- PKE Nasdaq
- ADCT Nasdaq
- Market Cap
- PKE 277.5M
- ADCT 285.2M
- IPO Year
- PKE N/A
- ADCT 2020
- Fundamental
- Price
- PKE $14.70
- ADCT $2.39
- Analyst Decision
- PKE
- ADCT Strong Buy
- Analyst Count
- PKE 0
- ADCT 5
- Target Price
- PKE N/A
- ADCT $7.33
- AVG Volume (30 Days)
- PKE 81.0K
- ADCT 392.5K
- Earning Date
- PKE 01-07-2025
- ADCT 11-07-2024
- Dividend Yield
- PKE 3.40%
- ADCT N/A
- EPS Growth
- PKE N/A
- ADCT N/A
- EPS
- PKE 0.34
- ADCT N/A
- Revenue
- PKE $58,651,000.00
- ADCT $70,717,000.00
- Revenue This Year
- PKE N/A
- ADCT $6.66
- Revenue Next Year
- PKE N/A
- ADCT $16.38
- P/E Ratio
- PKE $43.26
- ADCT N/A
- Revenue Growth
- PKE 5.81
- ADCT N/A
- 52 Week Low
- PKE $11.96
- ADCT $0.64
- 52 Week High
- PKE $16.96
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- PKE 58.59
- ADCT 31.47
- Support Level
- PKE $14.46
- ADCT $2.76
- Resistance Level
- PKE $15.36
- ADCT $3.06
- Average True Range (ATR)
- PKE 0.42
- ADCT 0.22
- MACD
- PKE 0.04
- ADCT -0.05
- Stochastic Oscillator
- PKE 67.08
- ADCT 6.63
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.